$0.94 EPS Expected for Ansys, Inc. (ANSS); Fresenius Medical Care AG & Co. KGAA (FMS) Had 5 Bullish Analysts

February 15, 2018 - By Hazel Jackson

Analysts expect Ansys, Inc. (NASDAQ:ANSS) to report $0.94 EPS on February, 28.They anticipate $0.02 EPS change or 2.17% from last quarter’s $0.92 EPS. ANSS’s profit would be $79.77 million giving it 41.94 P/E if the $0.94 EPS is correct. After having $0.88 EPS previously, Ansys, Inc.’s analysts see 6.82% EPS growth. The stock increased 2.27% or $3.5 during the last trading session, reaching $157.7. About 321,890 shares traded. Ansys, Inc. (NASDAQ:ANSS) has risen 43.75% since February 15, 2017 and is uptrending. It has outperformed by 27.05% the S&P500.

Among 8 analysts covering Fresenius Medical (NYSE:FMS), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Fresenius Medical had 17 analyst reports since July 31, 2015 according to SRatingsIntel. On Wednesday, November 4 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The firm has “Buy” rating by SunTrust given on Wednesday, December 20. RBC Capital Markets maintained Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) on Thursday, October 12 with “Hold” rating. As per Friday, July 8, the company rating was upgraded by Jefferies. RBC Capital Markets maintained Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) on Monday, September 11 with “Hold” rating. As per Thursday, March 17, the company rating was initiated by Nomura. Morgan Stanley downgraded the shares of FMS in report on Monday, December 11 to “Equal-Weight” rating. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 2. The firm has “Buy” rating given on Thursday, September 3 by Goldman Sachs. The firm has “Overweight” rating given on Monday, January 4 by JP Morgan. See Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) latest ratings:

20/12/2017 Broker: SunTrust Rating: Buy New Target: $62.0 Maintain
11/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $50.0 Maintain
02/11/2017 Broker: SunTrust Rating: Buy New Target: $57.0 Maintain
12/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain
11/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. The company has market cap of $31.62 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. It has a 23.27 P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

The stock increased 2.04% or $1.08 during the last trading session, reaching $54.04. About 137,060 shares traded. Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) has risen 11.17% since February 15, 2017 and is uptrending. It has underperformed by 5.53% the S&P500.

Since February 1, 2018, it had 0 buys, and 1 sale for $4.06 million activity. Shares for $4.06 million were sold by SHIELDS MARIA T on Thursday, February 1.

Among 15 analysts covering Ansys Inc. (NASDAQ:ANSS), 3 have Buy rating, 2 Sell and 10 Hold. Therefore 20% are positive. Ansys Inc. had 35 analyst reports since August 6, 2015 according to SRatingsIntel. Robert W. Baird maintained Ansys, Inc. (NASDAQ:ANSS) on Monday, August 28 with “Buy” rating. As per Friday, May 6, the company rating was downgraded by Wedbush. Berenberg initiated the shares of ANSS in report on Wednesday, August 23 with “Hold” rating. The company was maintained on Tuesday, February 16 by Wedbush. The stock of Ansys, Inc. (NASDAQ:ANSS) earned “Underweight” rating by Barclays Capital on Friday, September 15. The stock has “Hold” rating by Evercore on Wednesday, August 2. The firm earned “Sector Weight” rating on Thursday, October 8 by KeyBanc Capital Markets. The rating was maintained by J.P. Morgan on Thursday, September 14 with “Sell”. The stock of Ansys, Inc. (NASDAQ:ANSS) has “Equal Weight” rating given on Thursday, October 8 by Pacific Crest. The firm has “Hold” rating by Evercore given on Friday, June 9.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: